Philogen SpA
78Q
Company Profile
Business description
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
Contact
Piazza La Lizza No. 7
Siena53100
ITAT: +39 57717816
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
230
Stocks News & Analysis
stocks
Apple earnings: A smooth transition despite continued memory and supply headwinds
Shares fell as investors digested the latest earnings.
stocks
Big four bank holds up in weakening economic conditions
Major bank earnings hold up in challenging conditions.
stocks
Our view after Coles’ shares plunge
Shares dropped 8% after reporting results for the September 2026 quarter.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,981.00 | 3.80 | 0.04% |
| CAC 40 | 8,047.69 | 78.27 | 0.98% |
| DAX 40 | 25,981.09 | 162.88 | 0.63% |
| Dow JONES (US) | 51,983.98 | 213.67 | 0.41% |
| FTSE 100 | 10,761.33 | 31.55 | 0.29% |
| HKSE | 23,485.72 | 92.40 | 0.39% |
| NASDAQ | 25,164.31 | 272.68 | -1.07% |
| Nikkei 225 | 63,081.86 | 208.25 | -0.33% |
| NZX 50 Index | 13,699.12 | 0.49 | 0.00% |
| S&P 500 | 7,541.40 | 38.67 | -0.51% |
| S&P/ASX 200 | 8,859.60 | 3.10 | 0.04% |
| SSE Composite Index | 3,603.97 | 34.06 | -0.94% |